secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001193125-26-121780
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports Q4 net loss $43.7M; REMAIN-1 pivotal randomization complete
--------------------------------------------------------------------------------

- Net loss $43.7M for Q4 2025 vs $25.0M year ago; non-cash warrant liability change drove increase.
- Cash $81.5M as of Dec 31, 2025; cash runway into early 2027 beyond pivotal readout.
- Completed REMAIN-1 Pivotal Cohort randomization; topline 6-month data expected early Q4 2026.
- FDA feedback supports Class II De Novo pathway; potential De Novo submission late Q4 2026.
- Post-hoc analyses show ablation-length-dependent treatment effect; 70% reduction in weight regain in above-median GLP-1 loss group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526121780/0001193125-26-121780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526121780/guts-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-121780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer